Role of FDG PET-CT in recurrent renal cell carcinoma.
ABSTRACT To determine the efficacy of positron emission tomography-computed tomography using F-18 fluoro-deoxy-glucose (F-18 FDG PET-CT) in diagnosing the recurrence of renal cell carcinoma (RCC) in patients treated earlier with partial or radical nephrectomy.
We assessed 63 patients with suspected recurrent RCC after nephrectomy. PET-CT findings were interpreted as positive if the focal area of FDG uptake in the abdomen or outside the abdomen was more than the surrounding background tissue. The final diagnosis of the recurrence of RCC was based on histological examination and/or clinical follow-up and conventional imaging modalities.
A total of 103 PET-CT studies were done in these 63 patients, of which 63 studies were true positive, 30 studies were true negative, seven studies were false negative and remaining three studies were false positive. In 63 true-positive scans, PET-CT showed 109 lesions. Of these, 28 lesions were in the lungs, 21 lesions were at a locoregional site, 21 were in the bones, 12 in the retroperitoneal lymph nodes and 27 at other sites. The sensitivity, specificity and accuracy of PET-CT were 90, 91 and 90%, respectively.
Our results seem to confirm the useful role of PET-CT in the evaluation of post-surgical recurrence in patients who had undergone radical surgery for RCC.
Article: Spectrum of malignant renal and urinary bladder tumors on (18)F-FDG PET/CT: a pictorial essay.[show abstract] [hide abstract]
ABSTRACT: A wide variety of malignant renal and urinary bladder diseases can be detected on (18)F-FDG PET/CT. Although the PET/CT findings are often nonspecific, the aim of this atlas was to demonstrate that the spectrum of renal and urinary bladder malignancy that can be evaluated with PET/CT is much broader than current medical literature would suggest. PET/CT readers and oncologists should be aware of the variety of urological tumor types that can be detected on PET/CT and some of the patterns of (18)F-FDG uptake that can be observed in these cases.Clinical imaging 11/2012; 36(6):660-73. · 0.73 Impact Factor